Skip to content
Trending storyDeveloping

MedCram: Omicron sublineage NB.1.8.1 spreads as interferon-lambda trial shows 50% protection

1 report1 sourceupdated 3 hours ago

Start here

Synthesis

The SARS-CoV-2 Omicron sublineage NB.1.8.1, known as Nimbus, was first detected in China in January 2025 and is listed by WHO as a variant under monitoring. It grew from 2.5% to 10.7% of globally sequenced cases by April 2025 and exceeds 40% in Victoria, Australia. The variant shows higher ACE2 binding affinity and roughly 1.5-1.6-fold reduced neutralization compared with LP.8.1, but no evidence of increased severity. Separately, a NEJM randomized trial of nearly 2000 people found a single dose of pegylated interferon-lambda reduced the 28-day risk of hospitalization or emergency visits by about 50%, regardless of vaccination status. The lecture also noted that HHS cancelled over $700 million in Moderna H5N1 mRNA vaccine funding.

Written by a model from the reports · updated 2 hours ago

Coverage timeline

Follow the coverage to see the different angles.

Oct 14
  1. youtube.com
    MedCram analysis: NB.1.8.1 (Nimbus) spread and interferon-lambda trial evidence

    MedCram's expert lecture covers the SARS-CoV-2 Omicron sublineage NB.1.8.1 (Nimbus), first detected in China in January 2025 and listed by WHO as a variant under monitoring, which rose from 2.5% to 10.7% of global sequenced cases by April 2025 and exceeds 40% in Victoria, Australia. It shows higher ACE2 binding affinity and roughly 1.5-1.6-fold reduced neutralization versus LP.8.1, without increased severity. A NEJM randomized trial of nearly 2000 people found a single dose of pegylated interferon-lambda cut 28-day hospitalization or emergency-visit risk by about 50% regardless of vaccination status. The lecture also notes HHS cancelled over $700 million in Moderna H5N1 mRNA vaccine funding.

Heat trend for this story

Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –

02.557.510Oct18Oct18Oct18Oct18

The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org